These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 12702974)

  • 1. Optimizing the therapeutic potential of azathioprine/6-mercaptopurine in the treatment of inflammatory bowel disease.
    Papadakis KA
    J Clin Gastroenterol; 2003; 36(5):379-81. PubMed ID: 12702974
    [No Abstract]   [Full Text] [Related]  

  • 2. Optimizing thiopurine therapy in inflammatory bowel disease.
    Chevaux JB; Peyrin-Biroulet L; Sparrow MP
    Inflamm Bowel Dis; 2011 Jun; 17(6):1428-35. PubMed ID: 20949566
    [TBL] [Abstract][Full Text] [Related]  

  • 3. What are the rules when treatment with 6-MP/AZA is started?
    Korelitz BI
    Inflamm Bowel Dis; 2008 Oct; 14 Suppl 2():S262-3. PubMed ID: 18816727
    [No Abstract]   [Full Text] [Related]  

  • 4. Enhanced bioavailability of azathioprine compared to 6-mercaptopurine therapy in inflammatory bowel disease: correlation with treatment efficacy.
    Cuffari C; Hunt S; Bayless TM
    Aliment Pharmacol Ther; 2000 Aug; 14(8):1009-14. PubMed ID: 10930894
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Use of 6-mercaptopurine in patients with inflammatory bowel disease previously intolerant of azathioprine.
    Bowen DG; Selby WS
    Dig Dis Sci; 2000 Sep; 45(9):1810-3. PubMed ID: 11052324
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Thiopurines in Inflammatory Bowel Disease: New Findings and Perspectives.
    de Boer NKH; Peyrin-Biroulet L; Jharap B; Sanderson JD; Meijer B; Atreya I; Barclay ML; Colombel JF; Lopez A; Beaugerie L; Marinaki AM; van Bodegraven AA; Neurath MF
    J Crohns Colitis; 2018 Apr; 12(5):610-620. PubMed ID: 29293971
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Optimizing 6-mercaptopurine and azathioprine therapy in the management of inflammatory bowel disease.
    Bradford K; Shih DQ
    World J Gastroenterol; 2011 Oct; 17(37):4166-73. PubMed ID: 22072847
    [TBL] [Abstract][Full Text] [Related]  

  • 8. TPMT status determination: the simplest is the most effective?
    Chouchana L; Narjoz C; Loriot MA
    J Crohns Colitis; 2012 Aug; 6(7):807; author reply 808. PubMed ID: 22542920
    [No Abstract]   [Full Text] [Related]  

  • 9. Monitoring of azathioprine/6-mercaptopurine treatment in children with IBD is not necessary.
    Griffiths AM
    Inflamm Bowel Dis; 2003 Nov; 9(6):389-91; discussion 392-3. PubMed ID: 14671489
    [No Abstract]   [Full Text] [Related]  

  • 10. [Genetic polymorphism and treatment of chronic bowel inflammatory diseases: the example of azathioprine].
    Bessard G; Hardy G; Chartier A; Stanke-Labesque F
    Therapie; 2004; 59(1):71-5. PubMed ID: 15199672
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Rac1 as a Potential Pharmacodynamic Biomarker for Thiopurine Therapy in Inflammatory Bowel Disease.
    Seinen ML; van Nieuw Amerongen GP; de Boer NK; Mulder CJ; van Bezu J; van Bodegraven AA
    Ther Drug Monit; 2016 Oct; 38(5):621-7. PubMed ID: 27465973
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Optimized thiopurine treatment in chronic inflammatory bowel disease].
    Kiszka-Kanowitz M; Theede K; Nielsen AM
    Ugeskr Laeger; 2014 May; 176(22):. PubMed ID: 25352005
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Bioequivalence of azathioprine products.
    Baker DE
    Rev Gastroenterol Disord; 2003; 3(4):219-23. PubMed ID: 14668694
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Erythrocyte activity of thiopurine methyltransferase and treatment with thiopurines in inflammatory bowel disease].
    Domènech Morral E; Gassull Duro MA
    Med Clin (Barc); 2005 Sep; 125(8):293-4. PubMed ID: 16159553
    [No Abstract]   [Full Text] [Related]  

  • 15. Optimizing treatment with thioguanine derivatives in inflammatory bowel disease.
    Louis E; Belaiche J
    Best Pract Res Clin Gastroenterol; 2003 Feb; 17(1):37-46. PubMed ID: 12617881
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacogenomics and IBD: TPMT and thiopurines.
    Sandborn WJ
    Inflamm Bowel Dis; 2004 Feb; 10 Suppl 1():S35-7. PubMed ID: 15168829
    [No Abstract]   [Full Text] [Related]  

  • 17. Treatment of inflammatory bowel disease with azathioprine and 6-mercaptopurine.
    Su C; Lichtenstein GR
    Gastroenterol Clin North Am; 2004 Jun; 33(2):209-34, viii. PubMed ID: 15177535
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Erythrocyte mean corpuscular volume as a surrogate marker for 6-thioguanine nucleotide concentration monitoring in patients with inflammatory bowel disease treated with azathioprine or 6-mercaptopurine.
    Thomas CW; Lowry PW; Franklin CL; Weaver AL; Myhre GM; Mays DC; Tremaine WJ; Lipsky JJ; Sandborn WJ
    Inflamm Bowel Dis; 2003 Jul; 9(4):237-45. PubMed ID: 12902847
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Epstein-Barr virus-positive lymphoma in patients with inflammatory bowel disease treated with azathioprine or 6-mercaptopurine.
    Dayharsh GA; Loftus EV; Sandborn WJ; Tremaine WJ; Zinsmeister AR; Witzig TE; Macon WR; Burgart LJ
    Gastroenterology; 2002 Jan; 122(1):72-7. PubMed ID: 11781282
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Indicators of clinical response to treatment with six-mercaptopurine or azathioprine in patients with inflammatory bowel disease.
    Achkar JP; Stevens T; Easley K; Brzezinski A; Seidner D; Lashner B
    Inflamm Bowel Dis; 2004 Jul; 10(4):339-45. PubMed ID: 15475740
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.